Current Edition

clinical

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast …

Continue Reading →